Abstrakt
Celem niniejszej pracy jest omówienie zagadnień związanych z Teranostyką – jej podstawami, zastosowaniami, jak również – przedstawienie obecnego stanu wiedzy dotyczącego Teranostyki i jej perspektyw ze szczególnym uwzględnieniem ewolucji terapii w Europie.
Bibliografia
[1] Pandian, S. A. M., Murugan, R., Sahil S. M., and Sakthi, M. K., Harnessing the Power of Theranostic Materials for Combining Therapy and Diagnostics. I-manager’s Journal of Chemical Sciences, 4(2), 1-7. January 2024. Doi: 10.26634/jchem.4.2.21102
[2] Schwarz SW, Decristoforo C. US and EU radiopharmaceutical diagnostic and therapeutic nonclinical study requirements for clinical trials authorizations and marketing authorizations. EJNMMI Radiopharm Chem. 2019 May 22;4(1):10. doi: 10.1186/s41181-019-0059-2. PMID: 31659486; PMCID: PMC6529498.
[3] Radzina M, Saule L, Mamis E, Koester U, Cocolios TE, Pajuste E et al. Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go? EJNMMI Radiopharm Chem. 2023 Oct 12;8(1):27. doi: 10.1186/s41181-023-00211-5. PMID: 37823964; PMCID: PMC10570248.
[4] Miederer M, Benešová-Schäfer M, Mamat C, Kästner D, Pretze M, Michler E et al. Alpha-Emitting Radionuclides: Current Status and Future Perspectives. Pharmaceuticals (Basel). 2024 Jan 8;17(1):76. doi: 10.3390/ph17010076. PMID: 38256909; PMCID: PMC10821197.
[5] Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: Making precision medicine possible. CA Cancer J Clin. 2023 May-Jun;73(3):255-274. doi: 10.3322/caac.21768. Epub 2023 Jan 9. PMID: 36622841.
[6] Jang A, Kendi AT, Sartor O. Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther Adv Med Oncol. 2023 Mar 4;15:17588359231157632. doi: 10.1177/17588359231157632. PMID: 36895851; PMCID: PMC9989419.
[7] Watabe T, Hirata K, Iima M, Yanagawa M, Saida T, Sakata A et al. Recent advances in theranostics and oncology PET: emerging radionuclides and targets. Ann Nucl Med. 2025 Sep;39(9):909-921. doi: 10.1007/s12149-025-02090-z. Epub 2025 Jul 27. PMID: 40717183; PMCID: PMC12378779.
[8] Dadgar H, Pashazadeh A, Norouzbeigi N, Assadi M, Al-Balooshi B, Baum RP et al. Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during 177Lu/225Ac treatment in neuroendocrine tumors and metastatic prostate cancer. Theranostics. 2025 Mar 18;15(10):4368-4397. doi: 10.7150/thno.107963. PMID: 40225563; PMCID: PMC11984387.
[9] Kolasińska-Ćwikła A. Radioligand therapy — personalized treatment for patients with neuroendocrine tumors. Oncology in Clinical Practice. 2023;19(2):101–109. doi:10.5603/OCP.2021.0043.
[10] Bodei L, Herrmann K, Schöder H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022 Aug;19(8):534-550. doi: 10.1038/s41571-022-00652-y. Epub 2022 Jun 20. PMID: 35725926; PMCID: PMC10585450.
[11] Weber WA, Barthel H, Bengel F, Eiber M, Herrmann K, Schäfers M. What Is Theranostics? J Nucl Med. 2023 May;64(5):669-670. doi: 10.2967/jnumed.123.265670. Epub 2023 Apr 13. PMID: 37055220.
[12] Hertz B. A tribute to Dr. Saul Hertz: The discovery of the medical uses of radioiodine. World J Nucl Med. 2019;18(1):8-12. doi:10.4103/wjnm.WJNM_107_18.
[13] Lawal IO, Abubakar SO, Ndlovu H, Mokoala KMG, More SS, Sathekge MM. Advances in Radioligand Theranostics in Oncology. Mol Diagn Ther. 2024 May;28(3):265-289. doi: 10.1007/s40291-024-00702-4. Epub 2024 Mar 31. PMID: 38555542.
[14] Andrea K. Miyahira and Howard R Soule, The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation. Journal of Nuclear Medicine, March 2022; 63(3):331-338. Doi:10.2967/jnumed.262997.
[15] O'Keefe DS, Bacich DJ, Huang SS, Heston WDW. A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies. J Nucl Med. 2018 Jul;59(7):1007-1013. doi: 10.2967/jnumed.117.203877. Epub 2018 Apr 19. PMID: 29674422; PMCID: PMC6910646.
[16] O'Dorisio TM, Harris AG, O'Dorisio MS. Evolution of Neuroendocrine Tumor Therapy. Surg Oncol Clin N Am. 2020 Apr;29(2):145-163. doi: 10.1016/j.soc.2019.11.002. PMID: 32151353; PMCID: PMC7702714.
[17] Levine R., Krenning EP. Clinical history of the theranostic radionuclide approach to neuroendocrine tumours and other types of cancer: historical review based on an interview of Eric P. Krenning by Rachel Levine. J Nucl Md. 2017; (Suppl 2):3S-9S. doi:10.2967/jnumed.116.186502.
[18] Burkett BJ, Bartlett DJ, McGarrah PW, Lewis AR, Johnson DR, Berberoğlu K, et al. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements. Radiol Imaging Cancer. 2023 Jul;5(4):e220157. doi: 10.1148/rycan.220157. PMID: 37477566; PMCID: PMC10413300.
[19] Ballinger JR. Theranostic radiopharmaceuticals: established agents in current use. Br J Radiol. 2018 Nov;91(1091):20170969. doi: 10.1259/bjr.20170969.
[20] ] Merkel C, Whicher CH, Bomanji J, et al. Realising the potential of radioligand therapy: policy solutions for the barriers to implementation across Europe. Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1335-1339. doi: 10.1007/s00259-020-04745-7. PMID: 32170345; PMCID: PMC7188707.
[21] Barca C, Griessinger CM, Faust A, Depke D, Essler M, Windhorst AD, Devoogdt N, Brindle KM, Schäfers M, Zinnhardt B, Jacobs AH. Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy. Pharmaceuticals (Basel). 2021 Dec 22;15(1):13. doi: 10.3390/ph15010013.
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Bez utworów zależnych 4.0 Międzynarodowe.
Prawa autorskie (c) 2026 Zeszyty Naukowe Wielkopolskiego Centrum Onkologii